| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Division of Oncology, Department of Medicine [V. L. S.], Department of Medicinal Chemistry [E. C. D.], Division of Hospital Dentistry, Department of Restorative Dentistry [B. S. J.], and Division of General Internal Medicine, University of Washington, Department of Medicine [M. B. P.], University of Washington, and Division of Molecular Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington 98195 [S. J. C.]
Retinoids mediate the normal growth of a variety of epithelial cells and may play an important role in the chemoprevention of breast cancer. Despite the widespread clinical use of retinoids, specific target genes that are regulated by retinoids are relatively poorly characterized. We reported previously that all-trans-retinoic acid (ATRA) mediates G1-S-phase arrest in normal human mammary epithelial cells (HMECs). The tumor suppressor gene p53 is thought to be a critical regulator of G1-S-phase arrest mediated by DNA-damaging agents such as chemotherapy and radiation. The role of p53 protein expression in G1-S-phase arrest mediated by the differentiating agent ATRA is unknown. Increased expression of p53 protein is observed in ATRA-treated HMECs at 72 h; however, initiation of G1-S-phase arrest starts at 24 h, suggesting that this observed induction of p53 is a secondary event. Using retroviral-mediated gene transfer, we expressed the E6 protein of the human papillomavirus strain 16 (HPV-16) in HMECs. The HPV-16 E6 protein binds to p53 and targets it for degradation. Western analysis confirmed that HPV-16 E6-transduced HMECs had markedly decreased levels of p53 protein expression. Suppression of cellular p53 levels in HMECs did not alter the sensitivity of HMECs to ATRA-mediated growth arrest. Our studies suggest that ATRA-mediated G1-S-phase arrest is independent of the level of p53 protein expression. We also tested the ability of estrogen and antiestrogens to induce growth arrest in HMECs lacking p53 expression and found no decrease in the sensitivity of these cells to these agents. Our results emphasize the chemotherapeutic potential of ATRA and antiestrogens, particularly for suppressing the growth of tumors lacking functional p53.
This article has been cited by other articles:
![]() |
S. M. McDaniel, C. O'Neill, R. P. Metz, E. Tarbutton, M. Stacewicz-Sapuntzakis, J. Heimendinger, P. Wolfe, H. Thompson, and P. Schedin Whole-Food Sources of Vitamin A More Effectively Inhibit Female Rat Sexual Maturation, Mammary Gland Development, and Mammary Carcinogenesis than Retinyl Palmitate J. Nutr., June 1, 2007; 137(6): 1415 - 1422. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. C. Dietze, M. L. Bowie, K. Mrozek, L. E. Caldwell, C. Neal, R. J. Marjoram, M. M. Troch, G. R. Bean, K. K. Yokoyama, C. A. Ibarra, et al. CREB-binding protein regulates apoptosis and growth of HMECs grown in reconstituted ECM via laminin-5 J. Cell Sci., November 1, 2005; 118(21): 5005 - 5022. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Tu, D. J. Jerry, B. Pazik, and S. Smith Schneider Sensitivity to DNA Damage Is a Common Component of Hormone-Based Strategies for Protection of the Mammary Gland Mol. Cancer Res., August 1, 2005; 3(8): 435 - 442. [Abstract] [Full Text] [PDF] |
||||
![]() |
L Hilakivi-Clarke, C Wang, M Kalil, R Riggins, and R G Pestell Nutritional modulation of the cell cycle and breast cancer Endocr. Relat. Cancer, December 1, 2004; 11(4): 603 - 622. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Izzo, V. A. Papadimitrakopoulou, D. D. Liu, P. L. C. den Hollander, I. M. Babenko, J. Keck, A. K. El-Naggar, D. M. Shin, J. J. Lee, W. K. Hong, et al. Cyclin D1 Genotype, Response to Biochemoprevention, and Progression Rate to Upper Aerodigestive Tract Cancer J Natl Cancer Inst, February 5, 2003; 95(3): 198 - 205. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. L. Seewaldt, K. Mrozek, R. Sigle, E. C. Dietze, K. Heine, D. M. Hockenbery, K. B. Hobbs, and L. E. Caldwell Suppression of p53 function in normal human mammary epithelial cells increases sensitivity to extracellular matrix-induced apoptosis J. Cell Biol., October 29, 2001; 155(3): 471 - 486. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. L. Seewaldt, K. Mrózek, E. C. Dietze, M. Parker, and L. E. Caldwell Human Papillomavirus Type 16 E6 Inactivation of p53 in Normal Human Mammary Epithelial Cells Promotes Tamoxifen-mediated Apoptosis Cancer Res., January 1, 2001; 61(2): 616 - 624. [Abstract] [Full Text] |
||||
![]() |
Y. Zhang, A. K. Rishi, M. I. Dawson, R. Tschang, L. Farhana, M. Boyanapalli, U. Reichert, B. Shroot, E. C. Van Buren, and J. A. Fontana S-phase Arrest and Apoptosis Induced in Normal Mammary Epithelial Cells by a Novel Retinoid Cancer Res., April 1, 2000; 60(7): 2025 - 2032. [Abstract] [Full Text] |
||||
![]() |
E. I. Salim, H. Wanibuchi, K. Morimura, S. Kim, Y. Yano, S. Yamamoto, and S. Fukushima Inhibitory effects of 1,3-diaminopropane, an ornithine decarboxylase inhibitor, on rat two-stage urinary bladder carcinogenesis initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine Carcinogenesis, February 1, 2000; 21(2): 195 - 203. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |